| | Cohort | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
| Age, median (IQR) | 71 (66, 74.25) | 57 | 73 | 78 | 69 | Sex, female (%) | 1 (25) | M | M | M | F | Day 1 APACHE II, median (IQR) | 32 (30, 35) | 27 | 31 | 34 | 38 | Day 1 SOFA II, median (IQR) | 11 (11, 11.25) | 11 | 11 | 12 | 11 | BMI, median (IQR) | 22.7 (22.59,25.63) | 22.29 | 22.69 | 22.79 | 34.16 | Coronary artery disease, n (%) | 1 (25) | N | N | N | Y | Hypertension, n (%) | 3 (75) | N | Y | Y | Y | Diabetes, n (%) | 2 (50) | N | N | Y | Y | Dyslipidemia, n (%) | 2 (50) | N | Y | Y | N | Obesity, n (%) | 1 (25) | N | N | N | Y | Duration of MV in days, median (IQR) | 25 (22.2, 28) | 20 | 27 | 31 | 23a | Days in the ICU, median (IQR) | 43 (35.3, 57.8) | 30 | 37 | 49 | 84 | Days of steroid use, median (IQR) | 1.5 (0, 4.25) | 0 | 0 | 8 | 3 | Days with paralytic use, median (IQR) | 5.5 (1.75, 9.25) | 9 | 1 | 10 | 2 | Days undergoing prone positioning while on MV, median (IQR) | 4 (2.25, 5) | 3 | 0 | 5 | 5 | iNO use, n (%) | 0 | N | N | N | N | Hydroxychloroquine use, n (%) | 0 | N | N | N | N | Tocilizumab use, n (%) | 0 | N | N | N | N | PEPP individual sessions, median (range) | 3 (2, 4.25) | 2 | 2 | 4 | 5 | Duration in days of PEPP, median (range) | 2.5 (2, 3.25) | 2 | 2 | 3 | 4 | Duration of individual PEPP sessions in hours, median (IQR) | 1.5 (1.2, 2.1) | 1.33, 0.42 | 1, 0.5 | 2, 1.5, 1.25, 1.5 | 2.33, 4.08, 3.67, 1.75 |
|
|
IQR = interquartile range, APACHE II = Acute Physiologic and Chronic Health Evaluation II score, SOFA = Sequential Organ Failure Assessment score, BMI = body mass index, MV = mechanical ventilation, ICU = intensive care unit, iNO = inhaled nitric oxide, and PEPP = postextubation prone positioning. aThe number of MV days prior to extubation.
|